Premium
Preliminary observations of malignant melanoma therapy using radiolabeled alpha‐methyltyrosine
Author(s) -
McLaughlin William H.,
Thramann William M.,
Lambrecht Richard M.,
Milius Richard A.,
Bloomer William D.
Publication year - 1988
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930370312
Subject(s) - melanoma , cytotoxic t cell , clonogenic assay , medicine , cancer research , thymidine , cytotoxicity , melanin , nuclear medicine , radiochemistry , in vitro , chemistry , biochemistry
A strategy for cancer therapy using astatine‐211‐labeled alpha‐methyltyrosine ( 211 At‐AMT) was studied in cultured B16 melanoma cells and compared to the radiotoxicity of iodine‐125‐labeled iododeoxyuridine ( 125 IUdR), a thymidine analogue. Both 125 I and 211 At deliver lethal doses of irradiation to melanoma cells when administered as 125 IUdR and 211 At‐AMT. The alpha decay of astatine‐211 is more effective however, needing only a fraction of the cellular radioactivity of 125 IUdR to effect comparable clonogenic survival. Compared with 125 IUdR, 125 I‐AMT is not cytotoxic because the range of the low energy electrons released does not interact with DNA. Uptake of radiolabeled AMT by melanotic cells is enhanced by theophylline. This preliminary evidence suggests that 211 At‐labeled melanin precursors may be exquisitely cytotoxic to B16 melanoma cells.